Literature DB >> 8993213

Advances in the treatment of multiple sclerosis.

L B Krupp.   

Abstract

Entities:  

Mesh：

Year:  1996        PMID： 8993213      PMCID： PMC1303860     

Source DB:  PubMed          Journal:  West J Med        ISSN： 0093-0415


× No keyword cloud information.
  6 in total

Review 1.  Current pharmacologic treatment of multiple sclerosis symptoms.

Authors:  P B Andersson; D E Goodkin
Journal:  West J Med       Date:  1996-11

2.  Copolymer 1 reduces relapse rate and improves disability in relapsing-remitting multiple sclerosis: results of a phase III multicenter, double-blind placebo-controlled trial. The Copolymer 1 Multiple Sclerosis Study Group.

Authors:  K P Johnson; B R Brooks; J A Cohen; C C Ford; J Goldstein; R P Lisak; L W Myers; H S Panitch; J W Rose; R B Schiffer
Journal:  Neurology       Date:  1995-07       Impact factor: 9.910

3.  Tizanidine treatment of spasticity caused by multiple sclerosis: results of a double-blind, placebo-controlled trial. US Tizanidine Study Group.

Authors:  C Smith; G Birnbaum; J L Carter; J Greenstein; F D Lublin
Journal:  Neurology       Date:  1994-11       Impact factor: 9.910

Review 4.  Management of patients receiving interferon beta-1b for multiple sclerosis: report of a consensus conference.

Authors:  F D Lublin; J N Whitaker; B H Eidelman; A E Miller; B G Arnason; J S Burks
Journal:  Neurology       Date:  1996-01       Impact factor: 9.910

5.  Intramuscular interferon beta-1a for disease progression in relapsing multiple sclerosis. The Multiple Sclerosis Collaborative Research Group (MSCRG)

Authors:  L D Jacobs; D L Cookfair; R A Rudick; R M Herndon; J R Richert; A M Salazar; J S Fischer; D E Goodkin; C V Granger; J H Simon; J J Alam; D M Bartoszak; D N Bourdette; J Braiman; C M Brownscheidle; M E Coats; S L Cohan; D S Dougherty; R P Kinkel; M K Mass; F E Munschauer; R L Priore; P M Pullicino; B J Scherokman; R H Whitham
Journal:  Ann Neurol       Date:  1996-03       Impact factor: 10.422

6.  Impact of aerobic training on fitness and quality of life in multiple sclerosis.

Authors:  J H Petajan; E Gappmaier; A T White; M K Spencer; L Mino; R W Hicks
Journal:  Ann Neurol       Date:  1996-04       Impact factor: 10.422
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.